This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

When taken for 40 weeks for type 2 diabetes, orforglipron resulted in an average loss of 16 pounds, or about 7.9% of the patient's body weight, at the highest dose. HealthDay News — A new pill ...

And the results are exciting." On Thursday, Eli Lilly released data on Phase 3 trials of an experimental, daily weight-loss pill that neither requires refrigeration nor food or water upon ingestion.

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

The company’s shares jumped 15% in the wake of the trials which showed the pill, called orforglipron, helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable ...

The successful trial of a daily weight-loss pill has been hailed as a “landmark moment” in the fight against obesity, with Ireland’s leading expert in the field describing it as a “huge ...

Pfizer was forced to abandon its most advanced candidate after one patient in a clinical trial developed signs of liver injury. AstraZeneca is still working on its own weight-loss pills ...

announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for diabetes and weight loss. The trial of the drug ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, sending shares in the US drugmaker up nearly 15 per cent in Wall Street ...